Product details
Felycin-CA1 (sirolimus delayed-release tablets) contains sirolimus, an mTOR Inhibitor indicated for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM).
This product is a delayed-release tablet formulation.
- Conditionally approved by the FDA for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM).
- Once-weekly tablets are supplied in 12-count cartons and are available in three strengths: 0.4 mg, 1.2 mg, and 2.4 mg.
- Felycin-CA1 delayed-release tablets should be swallowed whole; do not split, crush, or allow your pet to chew tablets.
- Do not administer Felycin-CA1 to cats with pre-existing liver disease or diabetes mellitus.
- Sirolimus is classified as a hazardous drug and should be handled with extreme care; those who are pregnant or breastfeeding should avoid contact with Felycin-CA1.
Product sourced directly from the manufacturer or their approved distributor. Guaranteed genuine product backed by the manufacturer.
For
Cats
Active ingredient(s)
Sirolimus
Inactive ingredients
Sucrose, microcrystalline cellulose, crospovidone, poloxamer 188, glyceryl monooleate, povidone, anhydrous citric acid, talc.
Please note: The inactives listed above may only be a partial list, as the manufacturer does not explicitly provide a complete inactive ingredients list.
Brand name
Felycin-CA1
Drug class
mTOR inhibitor
Product flavoring
Felycin-CA1 enteric film-coated tablets are not flavored.
Manufacturer
PRN Pharmacal
Product strength & size
Felycin-CA1 delayed-release tablets are supplied in 12-tablet cartons and are available in three strengths: 0.4 mg, 1.2 mg, and 2.4 mg. The enteric film-coated tablets are sealed within a child resistant blister pack. Please ensure the selected product is appropriate for your pet, as recommended by your veterinarian.
For current availability, please refer to the product selection above.
Usage
*For complete product information including the manufacturer’s recommended Dosage and Administration, please review the full prescribing information/package insert.
Felycin-CA1 Tablets should be given orally as directed by your veterinarian. This medication should be given with a meal. Due to the available tablet strengths, cats weighing less than 2.5 kg (~5.5 pounds) cannot be accurately dosed.
Felycin-CA1 delayed-release tablets should be swallowed whole; do not split, crush, or allow your pet to chew tablets.
If you are pregnant or breastfeeding: avoid handling this medication.
All pet owners should wash their hands with soap and water after handling the medication, or if contact is made with the litter or bodily fluids of a treated cat (even if gloves are worn).
Please consult your veterinarian before making any changes or discontinuing the prescribed dosing schedule. Your veterinarian will monitor your pet’s bloodwork while taking this medication.
Missed doses
Administer the dose as soon as possible. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not give more medication than prescribed or two doses at once.
If you have questions about a missed dose or your pet’s prescribed dosing schedule (e.g., timing, interval), please consult your veterinarian.
Storage
Store in a cool, dry place at a controlled room temperature (68 to 77°F, excursions permitted between 59 and 86°F). Keep in a secure location out of the reach of children and pets. Tablets should remain sealed in the original packaging and only taken out of the blister pack at the time of dosing. Store away from heat and direct sunlight.
Do not store in the bathroom, near the kitchen sink, or in damp places. The medicine may break down if exposed to heat or moisture.
Side effects
The most frequently observed adverse effects in cats treated with Felycin-CA1 were cardiovascular in nature, relating to the progression of HCM, and included arrhythmia, congestive heart failure, syncope, and pericardial effusion.
Other adverse effects observed in cats treated with Felycin-CA1 were lethargy, vomiting, diarrhea, and inappetence.
Notify your veterinarian if your pet experiences any of the effects described above, or if you notice any other side effects that are persistent or troublesome.
If you notice anything unusual, please consult your veterinarian.
Precautions
*For complete product information including warnings and precautions, please refer to the manufacturer package insert.
For oral use in cats only- not for use in humans.
Do NOT administer Felycin-CA1 to cats with preexisting liver disease or diabetes mellitus. Discontinue immediately if a cat receiving Felycin-CA1 is diagnosed with diabetes mellitus.
Due to the available tablet strengths, cats weighing less than 2.5 kg (~5.5 pounds) cannot be accurately dosed.
Available information does not indicate that Felycin-CA1 is immunosuppressive at the recommended dosage. However, treatment may theoretically impact the treated cat's ability to mount an adequate immune response to vaccinations. The use of Felycin-CA1 in cats with chronic viral diseases has not been evaluated.
Use with caution in cats with the MDR1 mutation.
This medication should NOT be administered to pregnant animals or those that are used for breeding. Safe use of this medication has not been established and should be used with caution in nursing animals,
Do not administer to animals with a known history or suspected allergy/hypersensitivity to this medication or any of its ingredients. Allergic reactions to medications may occur. Be sure to inform Vetsource and your veterinarian if your pet has any known drug sensitivities or allergies.
If your pet displays symptoms of an allergic reaction, discontinue therapy and call your veterinarian immediately or seek emergency veterinary attention. Symptoms may include (but are not limited to): swollen lips, tongue, face, or airways; difficulty breathing; agitation; profuse salivation; and widespread hives or itching.
Human exposure warning
This medication is classified as hazardous due to potential exposure risks; individuals who are pregnant or breastfeeding should avoid contact with this medication, and those with a known hypersensitivity to sirolimus should exercise extreme caution if handling the medication is required.
Unopened, intact tablets may not pose the same degree of risk as injectable drugs, which usually require extensive preparation. Cutting, crushing, or otherwise manipulating tablets may increase the risk of exposure. Wearing gloves is recommended when handling this medication, and hands should be washed thoroughly with soap and water afterward (even if gloves are worn).
During normal handling, the coating on the tablets will prevent contact with the active ingredient, sirolimus. However, if the coating is broken down (e.g., through ingestion or vomiting by the cat), exposure can occur.
Ensure that any tablets that are not swallowed by the cat are disposed of immediately.
Avoid direct contact with vomit, saliva, or tablet remnants. When cleaning up vomit, saliva, or tablet remnants, wear gloves and wash hands afterwards.
Drug and food interactions
The following drugs* may have potential interactions with this medication:
ACE inhibitors (e.g., benazepril), antidiabetic agents (including insulins), azole antifungals (e.g., itraconazole, ketoconazole), calcium channel blockers (e.g., amlodipine, diltiazem, verapamil), corticosteroids (e.g., dexamethasone, prednisone), cyclosporine, eprinomectin, JAK inhibitors (e.g., Apoquel, Zenrelia), maropitant (Cerenia), metoclopramide, and phenobarbital.
*NOTE: this may not be a comprehensive list. Contact your veterinarian if your pet experiences any unusual reactions when different medications are given together.
Please ensure your veterinarian is aware of all medications and supplements that your pet is currently receiving. Your veterinarian may prescribe multiple medications, even if a potential drug interaction may occur. In these instances, your veterinarian may adjust the dosages or monitor your pet more closely.
Adverse reactions
If you are concerned that your pet has experienced an adverse reaction to this medication, please contact the manufacturer PRN Pharmacal at 1-800-874-9764 or Vetsource Pet Owner Care at 877-738-4443.
Overdose
If you have any reason to suspect an overdose, call your doctor/veterinarian or the appropriate poison control resource immediately.
For humans:
The national toll-free Poison Help line, 1-800-222-1222, will connect you to your local poison center in case of emergency. This service is available nationwide and in most U.S. territories.
For animals:
The ASPCA Animal Poison Control Center is available 24 hours a day, 365 days a year at 888-426-4435.
Pet Poison Helpline® also provides a 24/7 animal poison control service at 855-764-7661.
*Please note: this information is for third-party services and is provided for convenience in case of potential poison-related emergencies. There may be consultation fee for these services.
Disclaimer
The content provided on this page is NOT medical advice.
All content, including the images and product description above, is intended for general informational purposes only and should not be considered a substitute for professional veterinary consultation, diagnosis, or treatment.
Consult your veterinarian for complete information about this product and how it fits into your pet's individual treatment plan.
Last revised: 9/29/2025
-
Description
Product detailsFelycin-CA1 (sirolimus delayed-release tablets) contains sirolimus, an mTOR Inhibitor indicated for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM).This product is a delayed-release tablet formulation.- Conditionally approved by the FDA for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM).
- Once-weekly tablets are supplied in 12-count cartons and are available in three strengths: 0.4 mg, 1.2 mg, and 2.4 mg.
- Felycin-CA1 delayed-release tablets should be swallowed whole; do not split, crush, or allow your pet to chew tablets.
- Do not administer Felycin-CA1 to cats with pre-existing liver disease or diabetes mellitus.
- Sirolimus is classified as a hazardous drug and should be handled with extreme care; those who are pregnant or breastfeeding should avoid contact with Felycin-CA1.
Product sourced directly from the manufacturer or their approved distributor. Guaranteed genuine product backed by the manufacturer.ForCatsActive ingredient(s)SirolimusInactive ingredientsSucrose, microcrystalline cellulose, crospovidone, poloxamer 188, glyceryl monooleate, povidone, anhydrous citric acid, talc.Please note: The inactives listed above may only be a partial list, as the manufacturer does not explicitly provide a complete inactive ingredients list.Brand nameFelycin-CA1Drug classmTOR inhibitorProduct flavoringFelycin-CA1 enteric film-coated tablets are not flavored.ManufacturerPRN PharmacalProduct strength & sizeFelycin-CA1 delayed-release tablets are supplied in 12-tablet cartons and are available in three strengths: 0.4 mg, 1.2 mg, and 2.4 mg. The enteric film-coated tablets are sealed within a child resistant blister pack. Please ensure the selected product is appropriate for your pet, as recommended by your veterinarian.For current availability, please refer to the product selection above.Usage*For complete product information including the manufacturer’s recommended Dosage and Administration, please review the full prescribing information/package insert.Felycin-CA1 Tablets should be given orally as directed by your veterinarian. This medication should be given with a meal. Due to the available tablet strengths, cats weighing less than 2.5 kg (~5.5 pounds) cannot be accurately dosed.Felycin-CA1 delayed-release tablets should be swallowed whole; do not split, crush, or allow your pet to chew tablets.If you are pregnant or breastfeeding: avoid handling this medication.All pet owners should wash their hands with soap and water after handling the medication, or if contact is made with the litter or bodily fluids of a treated cat (even if gloves are worn).Please consult your veterinarian before making any changes or discontinuing the prescribed dosing schedule. Your veterinarian will monitor your pet’s bloodwork while taking this medication.Missed dosesAdminister the dose as soon as possible. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not give more medication than prescribed or two doses at once.If you have questions about a missed dose or your pet’s prescribed dosing schedule (e.g., timing, interval), please consult your veterinarian.StorageStore in a cool, dry place at a controlled room temperature (68 to 77°F, excursions permitted between 59 and 86°F). Keep in a secure location out of the reach of children and pets. Tablets should remain sealed in the original packaging and only taken out of the blister pack at the time of dosing. Store away from heat and direct sunlight.Do not store in the bathroom, near the kitchen sink, or in damp places. The medicine may break down if exposed to heat or moisture.Side effectsThe most frequently observed adverse effects in cats treated with Felycin-CA1 were cardiovascular in nature, relating to the progression of HCM, and included arrhythmia, congestive heart failure, syncope, and pericardial effusion.Other adverse effects observed in cats treated with Felycin-CA1 were lethargy, vomiting, diarrhea, and inappetence.Notify your veterinarian if your pet experiences any of the effects described above, or if you notice any other side effects that are persistent or troublesome.If you notice anything unusual, please consult your veterinarian.Precautions*For complete product information including warnings and precautions, please refer to the manufacturer package insert.For oral use in cats only- not for use in humans.Do NOT administer Felycin-CA1 to cats with preexisting liver disease or diabetes mellitus. Discontinue immediately if a cat receiving Felycin-CA1 is diagnosed with diabetes mellitus.Due to the available tablet strengths, cats weighing less than 2.5 kg (~5.5 pounds) cannot be accurately dosed.Available information does not indicate that Felycin-CA1 is immunosuppressive at the recommended dosage. However, treatment may theoretically impact the treated cat's ability to mount an adequate immune response to vaccinations. The use of Felycin-CA1 in cats with chronic viral diseases has not been evaluated.Use with caution in cats with the MDR1 mutation.This medication should NOT be administered to pregnant animals or those that are used for breeding. Safe use of this medication has not been established and should be used with caution in nursing animals,Do not administer to animals with a known history or suspected allergy/hypersensitivity to this medication or any of its ingredients. Allergic reactions to medications may occur. Be sure to inform Vetsource and your veterinarian if your pet has any known drug sensitivities or allergies.If your pet displays symptoms of an allergic reaction, discontinue therapy and call your veterinarian immediately or seek emergency veterinary attention. Symptoms may include (but are not limited to): swollen lips, tongue, face, or airways; difficulty breathing; agitation; profuse salivation; and widespread hives or itching.Human exposure warningThis medication is classified as hazardous due to potential exposure risks; individuals who are pregnant or breastfeeding should avoid contact with this medication, and those with a known hypersensitivity to sirolimus should exercise extreme caution if handling the medication is required.Unopened, intact tablets may not pose the same degree of risk as injectable drugs, which usually require extensive preparation. Cutting, crushing, or otherwise manipulating tablets may increase the risk of exposure. Wearing gloves is recommended when handling this medication, and hands should be washed thoroughly with soap and water afterward (even if gloves are worn).During normal handling, the coating on the tablets will prevent contact with the active ingredient, sirolimus. However, if the coating is broken down (e.g., through ingestion or vomiting by the cat), exposure can occur.Ensure that any tablets that are not swallowed by the cat are disposed of immediately.Avoid direct contact with vomit, saliva, or tablet remnants. When cleaning up vomit, saliva, or tablet remnants, wear gloves and wash hands afterwards.Drug and food interactionsThe following drugs* may have potential interactions with this medication: ACE inhibitors (e.g., benazepril), antidiabetic agents (including insulins), azole antifungals (e.g., itraconazole, ketoconazole), calcium channel blockers (e.g., amlodipine, diltiazem, verapamil), corticosteroids (e.g., dexamethasone, prednisone), cyclosporine, eprinomectin, JAK inhibitors (e.g., Apoquel, Zenrelia), maropitant (Cerenia), metoclopramide, and phenobarbital.*NOTE: this may not be a comprehensive list. Contact your veterinarian if your pet experiences any unusual reactions when different medications are given together.Please ensure your veterinarian is aware of all medications and supplements that your pet is currently receiving. Your veterinarian may prescribe multiple medications, even if a potential drug interaction may occur. In these instances, your veterinarian may adjust the dosages or monitor your pet more closely.Adverse reactionsIf you are concerned that your pet has experienced an adverse reaction to this medication, please contact the manufacturer PRN Pharmacal at 1-800-874-9764 or Vetsource Pet Owner Care at 877-738-4443.OverdoseIf you have any reason to suspect an overdose, call your doctor/veterinarian or the appropriate poison control resource immediately.For humans:The national toll-free Poison Help line, 1-800-222-1222, will connect you to your local poison center in case of emergency. This service is available nationwide and in most U.S. territories.For animals:The ASPCA Animal Poison Control Center is available 24 hours a day, 365 days a year at 888-426-4435.Pet Poison Helpline® also provides a 24/7 animal poison control service at 855-764-7661.*Please note: this information is for third-party services and is provided for convenience in case of potential poison-related emergencies. There may be consultation fee for these services.DisclaimerThe content provided on this page is NOT medical advice.All content, including the images and product description above, is intended for general informational purposes only and should not be considered a substitute for professional veterinary consultation, diagnosis, or treatment.Consult your veterinarian for complete information about this product and how it fits into your pet's individual treatment plan.Last revised: 9/29/2025 -
0 Reviews
